---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-029143"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:01:23.432323+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg

## Summary
- Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).
- GAAP net income $34.2M; Adjusted EBITDA $50.8M, up 59% YoY underlying.
- Began commercial-scale yield-enhanced IG manufacturing delivering 20%+ output gain.
- Closed $300M J.P. Morgan-led financing ($75M term loan, $225M revolver) replacing Ares debt.
- Reaffirmed FY2025-2026 guidance; pre-2030 revenue target $1.1B+; repurchased $15M stock.

## SEC filing metadata
- accession: 0001140361-25-029143
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-029143
- JSON: https://secwatch.observer/filing/0001140361-25-029143.json
- Plain text: https://secwatch.observer/filing/0001140361-25-029143.txt

## Key facts
- Debt Financings
  ADMA BIOLOGICS, INC. incurred term loan of $75 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.
  - Instrument: term loan
  - Principal: $75 million
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Rate: 150 basis points to 200 basis points over the alternate base rate and 250 basis
  - Maturity: August 5, 2028
  - Event: incurrence
  source text: The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the "Term Loan Facility") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the "Revolving Facility").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm
- Debt Financings
  ADMA BIOLOGICS, INC. incurred revolving credit of $225 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.
  - Instrument: revolving credit
  - Principal: $225 million
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Rate: 150 basis points to 200 basis points over the alternate base rate and 250 basis
  - Maturity: August 5, 2028
  - Event: incurrence
  source text: The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the "Term Loan Facility") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the "Revolving Facility").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm
- Debt Financings
  ADMA BIOLOGICS, INC. incurred credit facility of $300 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.
  - Instrument: credit facility
  - Principal: $300 million
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Rate: 150 basis points to 200 basis points over the alternate base rate and 250 basis
  - Maturity: August 5, 2028
  - Event: incurrence
  source text: into a Credit Agreement (the “Credit Agreement”), with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the “Term Loan Facility”) and (b) a revolving credit
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.